Orphan diseases compute: IBM bid by Novartis crashes, KPI powers up
Hoping to succeed where pharma giant Novartis AG failed in a late-stage trial, KPI Therapeutics Inc. is "working on closing out an investment round" to enable a phase II experiment with lead compound dalazatide in inclusion-body myositis (IBM), CEO Charles Magness told BioWorld Insight. "We hope to get that [financing] rolling in the summer-ish time frame," he said.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST